We have been establishing the partnership with other companies to accelerate the basic research, drug discovery, and development process to bring new selective anti-cancer medicines with a minimum risk of adverse reactions to patients as quick as possible. We shall continue to develop novel molecular-targeted medicines with expanding our partnership.
|
 |
